Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 2/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30041417 | 1.00 | NR3C2 (0.44) | NR3C2CCR2KDM4EGLSLCK | |
| SCHEMBL6320838 | 0.85 | NR3C2 (0.43) | NR3C2CCR2KDM4EGLSLCK | |
| SCHEMBL6720555 | 0.85 | CCNT1 (0.41) | NR3C2KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL6492788 | 0.84 | NR3C2 (0.45) | NR3C2CCR2GLSLCKMAPK8 | |
| SCHEMBL7380720 | 0.84 | GLS (0.41) | NR3C2CCR2KDM4EGLSLCK | |
| Hydrochloric Acid SCHEMBL28586309 | 0.83 | NR3C2 (0.44) | NR3C2CCR2GLSLCKMAPK8 | |
| SCHEMBL23666952 | 0.83 | NR3C2 (0.42) | NR3C2CCR2KDM4EGLSLCK | |
| SCHEMBL28580348 | 0.83 | NQO2 (0.49) | NR3C2CCR2KDM4EALDH1A1POLB | |
| SCHEMBL20098837 | 0.83 | CDK5 (0.44) | NR3C2CCR2GLSLCKSCN9A | |
| SCHEMBL465792 | 0.82 | CCR2 (0.42) | NR3C2CCR2GLSLCKMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336630-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORP (US) | 2024-10-10 | — | — | US | disclosed |
| US-12042495-B2 | MAP4K1 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-07-23 | — | — | US | disclosed |
| CN-117940406-A | MAP4K1 inhibitors | 缆图药品公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20230140954-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230140954-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-05-11 | — | — | US | disclosed |
| WO-2023288264-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023288264-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-01-19 | — | — | WO | disclosed |
| US-11534441-B2 | MAP4K1 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-27 | — | — | US | disclosed |
| US-11534441-B2 | MAP4K1 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-27 | — | — | US | disclosed |
| EP-4090663-A1 | MAP4K1 INHIBITORS | Blueprint Medicines Corporation (US) | 2022-11-23 | — | — | EP | disclosed |
| CN-115279771-A | MAP4K1 inhibitors | 缆图药品公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20220323438-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2022-10-13 | — | — | US | disclosed |
| WO-2021146370-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2021-07-22 | — | — | WO | disclosed |
| WO-2021146370-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2021-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11534441-B2 | MAP4K1 inhibitors | MAP4K1, MAP4K4, MAP4K2 | NR3C2 662/4885CCR2 3475/4885KDM4E 676/4885 |
| US-20240336630-A1 | MAP4K1 INHIBITORS | MAP4K1, MAP4K4, MAP4K2 | NR3C2 677/4885CCR2 3779/4885KDM4E 834/4885 |
| US-20220323438-A1 | MAP4K1 INHIBITORS | MAP4K1, MAP4K4, MAP4K2 | NR3C2 662/4885CCR2 3475/4885KDM4E 676/4885 |
| US-20230140954-A1 | MAP4K1 INHIBITORS | MAP4K1, MAP4K4, MAP4K2 | NR3C2 662/4885CCR2 3475/4885KDM4E 676/4885 |
| US-12042495-B2 | MAP4K1 inhibitors | MAP4K1, MAP4K4, MAP4K2 | NR3C2 662/4885CCR2 3475/4885KDM4E 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.